ECSP19048656A - COMPOSICIÓN FARMACÉUTICA ACUOSA DE ANTICUERPO MONOCLONAL RECOMBINANTE PARA EL FACTOR DE NECROSIS TUMORAL (TNF)a - Google Patents

COMPOSICIÓN FARMACÉUTICA ACUOSA DE ANTICUERPO MONOCLONAL RECOMBINANTE PARA EL FACTOR DE NECROSIS TUMORAL (TNF)a

Info

Publication number
ECSP19048656A
ECSP19048656A ECSENADI201948656A ECDI201948656A ECSP19048656A EC SP19048656 A ECSP19048656 A EC SP19048656A EC SENADI201948656 A ECSENADI201948656 A EC SENADI201948656A EC DI201948656 A ECDI201948656 A EC DI201948656A EC SP19048656 A ECSP19048656 A EC SP19048656A
Authority
EC
Ecuador
Prior art keywords
monoclonal antibody
aqueous pharmaceutical
recombinant monoclonal
tnf
pharmaceutical composition
Prior art date
Application number
ECSENADI201948656A
Other languages
English (en)
Inventor
Viktoriya Olegovna Shitikova
Aleksandr Olegovich Iakovlev
Ekaterina Aleksandrovna Lomkova
Anastasiya Mikhajlovna Ryakhovskaya
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2016152691A external-priority patent/RU2665966C2/ru
Priority claimed from RU2017146821A external-priority patent/RU2764521C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of ECSP19048656A publication Critical patent/ECSP19048656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors

Abstract

La invención se relaciona con composiciones farmacéuticas acuosas mejoradas de un anticuerpo monoclonal recombinante para TNFa; y un método de producción del mismo. La presente invención se relaciona además con el uso de composiciones farmacéuticas acuosas mejoradas de un anticuerpo monoclonal recombinante para TNFa; para tratar enfermedades mediadas por TNFa;. La invención propuesta permite la prevención de inestabilidad físico-química expresada en la formación de cúmulos y fragmentos de proteínas o en la modificación de proteínas en una solution; además, previene la inestabilidad durante la congelación/descongelación, la agitación y el movimiento.
ECSENADI201948656A 2016-12-30 2019-07-09 COMPOSICIÓN FARMACÉUTICA ACUOSA DE ANTICUERPO MONOCLONAL RECOMBINANTE PARA EL FACTOR DE NECROSIS TUMORAL (TNF)a ECSP19048656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016152691A RU2665966C2 (ru) 2016-12-30 2016-12-30 Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
RU2017146821A RU2764521C2 (ru) 2017-12-29 2017-12-29 Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОа

Publications (1)

Publication Number Publication Date
ECSP19048656A true ECSP19048656A (es) 2019-07-31

Family

ID=62710701

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201948656A ECSP19048656A (es) 2016-12-30 2019-07-09 COMPOSICIÓN FARMACÉUTICA ACUOSA DE ANTICUERPO MONOCLONAL RECOMBINANTE PARA EL FACTOR DE NECROSIS TUMORAL (TNF)a

Country Status (15)

Country Link
EP (1) EP3563867A4 (es)
JP (1) JP2020506955A (es)
KR (1) KR20190104043A (es)
AU (1) AU2017384942A1 (es)
BR (1) BR112019013673A2 (es)
CL (1) CL2019001818A1 (es)
CR (1) CR20190316A (es)
EC (1) ECSP19048656A (es)
JO (1) JOP20190162A1 (es)
MX (1) MX2019007911A (es)
NI (1) NI201900072A (es)
PE (1) PE20191550A1 (es)
PH (1) PH12019501530A1 (es)
WO (1) WO2018124948A1 (es)
ZA (1) ZA201904305B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152540A (ko) * 2020-03-13 2022-11-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
AU2022245592A1 (en) * 2021-03-24 2023-10-19 Jcr Pharmaceuticals Co., Ltd. Stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521206A (en) 1894-06-12 Frank b
EP0230574A3 (en) 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
SG43205A1 (en) 1988-12-19 1997-10-17 American Cyanamid Co A method for the treatment of endotoxic shock in a mammal
US6498237B2 (en) 1989-08-07 2002-12-24 Peptech Limited Tumor necrosis factor antibodies
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DK0604418T3 (da) 1991-03-29 1999-06-14 Immunex Corp Isolerede viralproteincytokinantagonister
WO1993011793A1 (en) 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
JP3251587B2 (ja) 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
ES2121907T3 (es) 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
JPH08509203A (ja) 1992-10-15 1996-10-01 ダナ−ファーバー キャンサー インステテュート インコーポレイテッド ＴＮＦ−α作用の拮抗剤を用いる肥満関連糖尿病▲ＩＩ▼型のインスリン耐性の治療
DE4307508A1 (de) 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
RU2595379C2 (ru) * 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
SG11201405475UA (en) * 2012-03-07 2014-10-30 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha antibodies
EP3250598A1 (en) * 2015-01-28 2017-12-06 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies

Also Published As

Publication number Publication date
JP2020506955A (ja) 2020-03-05
NI201900072A (es) 2019-10-31
MX2019007911A (es) 2019-12-05
JOP20190162A1 (ar) 2019-06-27
EP3563867A1 (en) 2019-11-06
WO2018124948A8 (ru) 2018-09-27
CR20190316A (es) 2019-09-04
BR112019013673A2 (pt) 2020-01-28
EP3563867A4 (en) 2020-12-16
PE20191550A1 (es) 2019-10-24
KR20190104043A (ko) 2019-09-05
AU2017384942A1 (en) 2019-08-08
ZA201904305B (en) 2022-04-28
PH12019501530A1 (en) 2020-02-24
CL2019001818A1 (es) 2019-11-29
WO2018124948A1 (ru) 2018-07-05

Similar Documents

Publication Publication Date Title
ECSP19048656A (es) COMPOSICIÓN FARMACÉUTICA ACUOSA DE ANTICUERPO MONOCLONAL RECOMBINANTE PARA EL FACTOR DE NECROSIS TUMORAL (TNF)a
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
PE20181092A1 (es) Anticuerpos anti-pd1 y metodos de uso
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
PH12019500596A1 (en) Recombinant binding proteins and their use
BR112016009797A2 (pt) anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
EA201792359A1 (ru) Композиция анти-cgrp антитела
MY185551A (en) Antibody formulations
EA202092735A1 (ru) Антагонизирующее cd73 антитело
CL2016001405A1 (es) A peptide mixture
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
EA201892097A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ
PE20170299A1 (es) Proteinas agonistas de los receptores de trail de cadena simple
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201892774A1 (ru) Антитела
EA201891788A1 (ru) Антитела к фно-альфа и их функциональные фрагменты
MX2015011846A (es) Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
AR099068A1 (es) Anticuerpo anti-netrina-1
WO2015187992A3 (en) Map44 polypeptides and constructs based on natural antibodies and uses thereof
EA202190807A1 (ru) Антитела к синуклеину